318 related articles for article (PubMed ID: 33562495)
1. Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer.
Mabuchi S; Sasano T; Komura N
Cells; 2021 Feb; 10(2):. PubMed ID: 33562495
[TBL] [Abstract][Full Text] [Related]
2. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
Front Immunol; 2019; 10():1273. PubMed ID: 31214202
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers.
Mabuchi S; Sasano T
Cells; 2021 Apr; 10(5):. PubMed ID: 33946532
[TBL] [Abstract][Full Text] [Related]
4. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
5. Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer.
Okła K; Czerwonka A; Wawruszak A; Bobiński M; Bilska M; Tarkowski R; Bednarek W; Wertel I; Kotarski J
Front Immunol; 2019; 10():691. PubMed ID: 31001284
[TBL] [Abstract][Full Text] [Related]
6. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
8. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cells and their role in gynecological malignancies.
Mabuchi S; Yokoi E; Komura N; Kimura T
Tumour Biol; 2018 Jul; 40(7):1010428318776485. PubMed ID: 30074452
[TBL] [Abstract][Full Text] [Related]
10. A Call for Epidemiological Research on Myeloid-Derived Suppressor Cells in Ovarian Cancer: A Review of the Existing Immunological Evidence and Suggestions for Moving Forward.
Stenzel AE; Abrams SI; Moysich KB
Front Immunol; 2019; 10():1608. PubMed ID: 31354741
[TBL] [Abstract][Full Text] [Related]
11. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.
Qu P; Wang LZ; Lin PC
Cancer Lett; 2016 Sep; 380(1):253-6. PubMed ID: 26519756
[TBL] [Abstract][Full Text] [Related]
12. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
13. Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils.
Khan ANH; Emmons TR; Wong JT; Alqassim E; Singel KL; Mark J; Smith BE; Tario JD; Eng KH; Moysich KB; Odunsi K; Abrams SI; Segal BH
Cancer Immunol Res; 2020 Jun; 8(6):819-828. PubMed ID: 32238380
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer.
Li L; Li M; Jia Q
Pathol Res Pract; 2023 Aug; 248():154711. PubMed ID: 37494802
[TBL] [Abstract][Full Text] [Related]
15. A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment.
Hofer F; Di Sario G; Musiu C; Sartoris S; De Sanctis F; Ugel S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685679
[TBL] [Abstract][Full Text] [Related]
16. Suppressing MDSC Infiltration in Tumor Microenvironment Serves as an Option for Treating Ovarian Cancer Metastasis.
Li Y; Zhang Q; Wu M; Zhang P; Huang L; Ai X; Yang Z; Shen Q; Wang Y; Wang P; Zhou S; He ML
Int J Biol Sci; 2022; 18(9):3697-3713. PubMed ID: 35813475
[TBL] [Abstract][Full Text] [Related]
17. Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells.
Horikawa N; Abiko K; Matsumura N; Hamanishi J; Baba T; Yamaguchi K; Yoshioka Y; Koshiyama M; Konishi I
Clin Cancer Res; 2017 Jan; 23(2):587-599. PubMed ID: 27401249
[TBL] [Abstract][Full Text] [Related]
18. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Komura N; Mabuchi S; Shimura K; Yokoi E; Kozasa K; Kuroda H; Takahashi R; Sasano T; Kawano M; Matsumoto Y; Kodama M; Hashimoto K; Sawada K; Kimura T
Cancer Immunol Immunother; 2020 Dec; 69(12):2477-2499. PubMed ID: 32561967
[TBL] [Abstract][Full Text] [Related]
19. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
[TBL] [Abstract][Full Text] [Related]
20. Monocytic and granulocytic myeloid-derived suppressor cell plasticity and differentiation are organ-specific.
Guha P; Gardell J; Rabinowitz B; Lopes M; DaSilva NA; Rowley D; Katz SC
Oncogene; 2021 Jan; 40(3):693-704. PubMed ID: 33230244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
